896 A PHASE III, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP, PLACEBO-CONTROLLED STUDY OF ORAL ALEDRONATE, 70 MG ONCE-A-WEEK, FOR THE PREVENTION OF ANDROGEN DEPRIVATION BONE LOSS IN NON-METASTATIC PROSTATE CANCER. A CANADIAN UROLOGY RESEARCH CONSORTIUM STUDY
Klotz, Laurence, McNeil, Irene, Kebabdjian, Marlene, Zhang, Liying, Chin, JosephVolume:
185
Language:
english
Journal:
The Journal of Urology
DOI:
10.1016/j.juro.2011.02.2605
Date:
April, 2011
File:
PDF, 45 KB
english, 2011